Friday, April 26, 2024
4/26/2024
Summary/Abstract Transplantation is a curative strategy for end stage organ failure. In order to avoid immune-mediated rejection of the grafted tissue, recipients receive life-long immunosuppression. Calcineurin and mTOR inhibitors for immunosuppression are successful in preventing graft rejection but are associated with significant adverse off- target toxicities. In order to better preserve the health of both the graft and the transplant recipient, alternative immunosuppressive therapies have been sought. Belatacept, a CTLA-4Ig fusion protein, suppresses the immune system by binding to CD80 and CD86 on antigen presenting cells (APCs) to block CD28 (costimulatory) and CTLA-4 (coinhibitory) signaling on T cells. By blocking interactions that are specific for immune cells, the use of CTLA-4Ig mitigates off-target toxicities associated with calcineurin inhibitors and increases the longevity of the graft and health of the patient. However, CTLA-4Ig is associated with increased risk of acute rejection episodes compared to calcineurin inhibitors, which has prohibited its widespread clinical adoption despite the improved long-term outcomes. Regulatory T cells are essential to maintaining immune homeostasis and promoting tolerance in transplant, but the blockade of signaling through CD28 and CTLA-4 is detrimental to their survival and function. Therefore, CTLA-4Ig therapy inhibits Tregs from controlling CD8+ T cells as they execute acute rejection. Identifying costimulatory and coinhibitory pathways that can be targeted to enhance the suppressive capacity of Tregs in the setting of CTLA-4Ig therapy is essential to improving targeted immunosuppressive therapies. TIGIT is a T-cell inhibitory receptor with Ig and ITIM domains expressed on Tregs that can be targeted with antibodies to fine-tune Treg function. Agonistic anti-TIGIT antibodies have been shown to induce apoptosis of costimulation blockade-resistant memory T cells in a Treg- dependent manner. The experiments outlined in this proposal study the mechanisms by which TIGIT signaling on Tregs enhances Treg function in the face of CTLA-4Ig therapy to reduce CD8 + T cell responses to allograft challenge. In Aim 1 we will determine if cell-autonomous TIGIT signaling increases the abundance of Tregs within grafted tissue and increases the secretion of suppressive molecules to enhance Treg function. In Aim 2 we will determine the impact of Treg-specific TIGIT signaling on effector CD8+ T cell responses to allograft. These studies will be performed using novel Treg-specific TIGIT knockout animals (Foxp3-Cre x TIGITfl/fl). Together, these data will illuminate the therapeutic potential of TIGIT agonism in combination with costimulation blockade therapeutics to mitigate acute allograft rejection.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
